FDA Response to COVID Gives Insights for Regulatory Future of LDTs
Certain temporary deviations in FDA policy in response to the COVID-19 pandemic may offer a blueprint for regulatory oversight of LDTs.
Read MorePosted by Chris Wolski | Sep 17, 2021 | Compliance |
Certain temporary deviations in FDA policy in response to the COVID-19 pandemic may offer a blueprint for regulatory oversight of LDTs.
Read MorePosted by Toni Mitchell | Sep 17, 2021 | Covid 19, Rapid Assays |
Rockefeller University’s “DRUL” saliva test performs as well as, if not better, than FDA-authorized nasal and oral swab tests.
Read MorePosted by Chris Wolski | Sep 16, 2021 | Disease States |
Cairn Diagnostics has announced that the U.S. FDA has expanded the approval of the company’s 13C-Spirulina GEBT to now include “at home” administration.
Read MorePosted by Chris Wolski | Sep 16, 2021 | Covid 19 |
Laboratorians are in a unique position to educate about the differences between professional, laboratory-grade COVID testing and at-home consumer tests.
Read MorePosted by Chris Wolski | Sep 15, 2021 | Benches |
Laboratory equipment is a vital for any healthcare enterprise and maximizing high-performance workstations is fundamental to laboratory workflow success.
Read More